Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

This study is testing a novel immune cell therapy using specially activated natural killer (NK) cells — a type of immune cell — combined with two immunotherapy drugs (nivolumab and relatlimab) for people with advanced melanoma whose cancer progressed despite previous immunotherapy. The goal is to re-engage the immune system against a tumor that has become resistant. **You may be eligible if...** - You are 18 or older with advanced or metastatic melanoma confirmed by biopsy - Your cancer progressed after at least 12 weeks (or 2 doses) of a standard PD-1 immunotherapy (such as nivolumab or pembrolizumab) - Your general health is reasonably good (ECOG ≤2) - Your organ function (liver, kidneys, heart) meets the required thresholds - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - You have an active autoimmune disease requiring immunosuppression - You have had a prior severe immune-related side effect (grade 3 or 4) from cancer immunotherapy (some exceptions apply) - You cannot come off corticosteroids or immunosuppressants for the required period before treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.